
Sharon X Xie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12008725/publications.pdf Version: 2024-02-01



SHADON X XIE

#	Article	IF	CITATIONS
1	Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain, 2013, 136, 2697-2706.	7.6	609
2	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain, 2018, 141, 2181-2193.	7.6	448
3	Neuropathologic substrates of Parkinson disease dementia. Annals of Neurology, 2012, 72, 587-598.	5.3	401
4	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurology, The, 2017, 16, 55-65.	10.2	394
5	Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathologica, 2007, 114, 221-229.	7.7	378
6	Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 227-231.	7.1	374
7	The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice. Journal of Neuroscience, 2012, 32, 3601-3611.	3.6	325
8	Questionnaire for impulsiveâ€compulsive disorders in Parkinson's Disease–Rating Scale. Movement Disorders, 2012, 27, 242-247.	3.9	263
9	Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy. Journal of Neuroscience, 2010, 30, 13861-13866.	3.6	256
10	Evidence of Multisystem Disorder in Whole-Brain Map of Pathological TDP-43 in Amyotrophic Lateral Sclerosis. Archives of Neurology, 2008, 65, 636-41.	4.5	251
11	Clinical and Pathological Continuum of Multisystem TDP-43 Proteinopathies. Archives of Neurology, 2009, 66, 180-9.	4.5	232
12	Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain, 2012, 135, 3749-3756.	7.6	228
13	Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain, 2012, 135, 807-818.	7.6	226
14	Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathologica, 2020, 140, 99-119.	7.7	210
15	Longitudinal study of normal cognition in Parkinson disease. Neurology, 2015, 85, 1276-1282.	1.1	197
16	Neurodegeneration Across Stages of Cognitive Decline in Parkinson Disease. Archives of Neurology, 2011, 68, 1562.	4.5	180
17	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimer's and Dementia, 2014, 10, 477.	0.8	167
18	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathologica, 2012, 124, 23-35.	7.7	161

SHARON X XIE

#	Article	IF	CITATIONS
19	Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. Brain, 2012, 135, 170-180.	7.6	149
20	Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathologica, 2012, 123, 395-407.	7.7	104
21	Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2017, 76, 270-288.	1.7	98
22	Pathological 43-kDa Transactivation Response DNA-Binding Protein in Older Adults With and Without Severe Mental Illness. Archives of Neurology, 2010, 67, 1238-50.	4.5	90
23	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. Annals of Neurology, 2019, 85, 259-271.	5.3	88
24	The development and convergence of co-pathologies in Alzheimer's disease. Brain, 2021, 144, 953-962.	7.6	76
25	Naltrexone for impulse control disorders in Parkinson disease. Neurology, 2014, 83, 826-833.	1.1	74
26	CSF tau and \hat{l}^2 -amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology, 2018, 90, e1038-e1046.	1.1	68
27	Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements inÂAlzheimer's Disease. Journal of Alzheimer's Disease, 2015, 48, 987-994.	2.6	67
28	Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathologica, 2015, 130, 363-372.	7.7	65
29	Building an integrated neurodegenerative disease database at an academic health center. Alzheimer's and Dementia, 2011, 7, e84-93.	0.8	63
30	CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathologica, 2014, 127, 621-632.	7.7	60
31	Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy. Acta Neuropathologica, 2011, 121, 509-517.	7.7	52
32	<i>TMEM106B</i> Effect on cognition in Parkinson disease and frontotemporal dementia. Annals of Neurology, 2019, 85, 801-811.	5.3	52
33	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. Annals of Neurology, 2017, 82, 247-258.	5.3	51
34	Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. Journal of Comparative Neurology, 2013, 521, 4339-4355.	1.6	47
35	Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain, 2020, 143, 2844-2857.	7.6	44
36	The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 25, 21-26.	2.2	42

SHARON X XIE

#	Article	IF	CITATIONS
37	<i>APOE</i> , thought disorder, and SPAREâ€AD predict cognitive decline in established Parkinson's disease. Movement Disorders, 2018, 33, 289-297.	3.9	35
38	Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. Journal of Neuropathology and Experimental Neurology, 2020, 79, 296-304.	1.7	35
39	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	12.8	34
40	Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS ONE, 2017, 12, e0177924.	2.5	33
41	Rate of Decline in Alzheimer Disease Measured by a Dementia Severity Rating Scale. Alzheimer Disease and Associated Disorders, 2009, 23, 268-274.	1.3	32
42	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. Movement Disorders, 2020, 35, 1618-1625.	3.9	31
43	Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. Acta Neuropathologica, 2022, 143, 15-31.	7.7	29
44	Amyloidâ€Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. Movement Disorders Clinical Practice, 2016, 3, 367-375.	1.5	28
45	An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia. PLoS ONE, 2016, 11, e0147319.	2.5	25
46	Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer's disease. Journal of the International Neuropsychological Society, 2010, 16, 278-286.	1.8	21
47	Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. Journal of Parkinson's Disease, 2017, 7, 385-395.	2.8	21
48	Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire. Movement Disorders, 2016, 31, 126-134.	3.9	20
49	Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases. Acta Neuropathologica, 2011, 122, 737-745.	7.7	15
50	Research consent capacity varies with executive function and memory in Parkinson's disease. Movement Disorders, 2016, 31, 414-417.	3.9	12
51	Signature laminar distributions of pathology in frontotemporal lobar degeneration. Acta Neuropathologica, 2022, 143, 363-382.	7.7	12
52	Trends in oral anticoagulant co-prescription with antiepileptic drugs among adults with epilepsy, 2010–2018. Epilepsy and Behavior, 2020, 113, 107550.	1.7	4